Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


PROSENSA HOLDING B.V. PRICES INITIAL PUBLIC OFFERING


Leiden, the Netherlands—June 27, 2013—Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share, before underwriting discounts. Prosensa has also granted the underwriters a 30-day option to purchase up to an additional 900,000 ordinary shares to cover over-allotments, if any. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2013 under the symbol “RNA.”

Prosensa intends to use the proceeds from the offering to fund its current DMD development portfolio, its early-stage DMD discovery work and DMD-support projects, to fund other non-DMD projects and for working capital and general corporate purposes.

J.P. Morgan and Citigroup are acting as joint book-running managers for the offering. Leerink Swann is acting as lead manager, and Wedbush PacGrow Life Sciences, KBC Securities and Trout Capital are acting as co-managers.

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on June 27, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204 or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 800-831-9146, email: batprospectusdept@citi.com. About Prosensa Holding B.V. Prosensa is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease.

Contacts:

Prosensa Holding B.V. Celia Economides, Director IR & Corporate Communications

Phone: +1 917 941 9059

Email: c.economides@prosensa.nl

Berndt Modig, CFO

Phone: +31-71-3322100

Email: b.modig@prosensa.nl

CollegeHill Life Sciences (European Media)

Sue Charles, Melanie Toyne Sewell, Veronica Sellar

Phone: +44 20 7457 2020

Email: prosensa@collegehill.com

Lazar Partners (US Media)

Fern Lazar, Hollister Hovey

Phone: +1 212 867 1762

Email: flazar@lazarpartners.com

hhovery@lazarpartners.com


Publisher Contact Information:

Prosensa B.V.
+31-71-3322100
b.modig@prosensa.nl

Company profile of Prosensa B.V.
Past press releases of Prosensa B.V. .

Data


26,126
Tech investments
From our Online Data Service
16,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.